BioCentury
ARTICLE | Company News

Impasse over Vertex CF drugs likely to continue despite NHS’s managed access offer

May 23, 2019 10:37 PM UTC

Despite including a key request from CF patient advocacy groups' wish list, a fresh proposal from NHS England is unlikely to break the three-year-long stalemate over access to Vertex's cystic fibrosis drugs.

NHS England's new offer would fund Orkambi ivacaftor/lumacaftor and Symkevi tezacaftor/ivacaftor for all eligible patients under a two-year managed access arrangement that would allow for the collection of real-world data that could then inform the drugs' appraisal by NICE. ...